Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intellia Therapeutics Inc NTLA

Healthcare Biotechnology
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its... see more

Recent & Breaking News (NDAQ:NTLA)

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2017 Earnings

GlobeNewswire October 30, 2017

Intellia Therapeutics to Present at October Healthcare Investor Conferences

GlobeNewswire October 3, 2017

Intellia Therapeutics Demonstrates Sustained and Durable Genome Editing with CRISPR/Cas9 in One-Year Animal Study

GlobeNewswire September 26, 2017

Intellia Therapeutics to Present at Upcoming September Investor Healthcare Conferences

GlobeNewswire September 7, 2017

15 Biggest Mid-Day Losers For Tuesday

Benzinga.com  August 29, 2017

Investors: Covered-call reports for Box, Foot Locker, Fabrinet, Intellia Therapeutics and Tenet Healthcare

PR Newswire August 22, 2017

 Intellia Therapeutics Announces Second Quarter 2017 Financial Results

GlobeNewswire August 1, 2017

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of U.S. Patent Board Decision on CRISPR/Cas9 Gene Editing

GlobeNewswire July 25, 2017

Intellia Therapeutics Names Moncef Slaoui, Ph.D. and Frank Verwiel, M.D. to Its Board of Directors and Establishes a Science and Technology Committee

GlobeNewswire July 24, 2017

6 Biotech Stocks Jefferies Says Are Undervalued

Benzinga.com  June 23, 2017

Intellia Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China

GlobeNewswire June 19, 2017

Intellia Therapeutics and San Raffaele University and Research Hospital to Combine CRISPR/Cas9 Genome Editing with Enhanced Cell Therapies to Fight Cancer

GlobeNewswire June 6, 2017

Intellia Therapeutics Announces Progress with CRISPR/Cas9 at the American Society of Gene & Cell Therapy Annual Meeting

GlobeNewswire May 13, 2017

Intellia Therapeutics Announces First Quarter 2017 Financial Results

GlobeNewswire May 2, 2017

Intellia Therapeutics and CRISPR Therapeutics Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein Complexes

GlobeNewswire April 26, 2017

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S. Patent Board Decision

GlobeNewswire April 13, 2017

Intellia Therapeutics Announces European Patent Office’s Decision to Grant CRISPR/Cas9 Genome Editing Technology Patent

GlobeNewswire April 11, 2017

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results

GlobeNewswire March 14, 2017

Intellia Therapeutics Demonstrates Pioneering CRISPR/Cas9 Genome Editing Efficiency Data Using Lipid Nanoparticle Delivery Technology

GlobeNewswire March 8, 2017

Intellia Therapeutics to Present at March Investor Healthcare Conferences

GlobeNewswire March 1, 2017